What Life Left In Synta's Ganetespib On Phase III failure?
This article was originally published in Scrip
Synta Pharmaceuticals is banking on better fortunes in ovarian, blood and breast cancers to keep hopes for its heat shock protein 90 inhibitor ganetespib alive after an ignominious futility failure for its Phase III GALAXY-2 trial in lung cancer.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.